Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Drammen – page 25

616 clinical trials in Drammen, Norway across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Drammen at a glance
616
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

616 trials in Drammen

Open in trial search

Oxaliplatin-based drug combination (including bevacizumab, tislelizumab, fluorouracil, folic acid) for patients with diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Akershus University Hospital

Multifocal motor neuropathy

Not yet recruiting

Phase 1b study of empasiprubart in adults with multifocal motor neuropathy to assess nerve morphology by ultrasound

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Ischaemic stroke

Not yet recruiting

A study to evaluate the use of tocilizumab in adults with acute ischemic stroke undergoing mechanical clot removal.

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Oslo University Hospital HF

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Renal transplant

Not yet recruiting

Effect of antimicrobial drugs on tacrolimus and mycophenolate mofetil pharmacokinetics in kidney transplant recipients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Oslo University Hospital HF

Non-small cell lung cancer

Not yet recruiting

Phase II Randomized Trial of Adjuvant Durvalumab Immunotherapy After Neoadjuvant Chemoimmunotherapy in Patients With Resectable Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Oslo University Hospital HF

Coronary artery disease

Not yet recruiting

Continuing vs Stopping Acetylsalicylic Acid in Elderly Patients with Chronic Coronary Syndrome (Secondary Prevention): A Randomized Trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Vestre Viken HF

Pulmonary embolism

Not yet recruiting

Reduced-dose versus full-dose alteplase for high-risk acute pulmonary embolism patients: a randomized multicenter trial

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:University Of Gothenburg

Spinal muscular atrophy

Not yet recruiting

Safety and Efficacy of Intrathecal BIIB115 in Infants with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Long QT syndrome

Not yet recruiting

Effect of estradiol‑based menopausal hormone therapy drug combination on QTc in peri‑ and postmenopausal women with genetically confirmed Long QT syndrome

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Estradiol
  • Sponsor:Oslo University Hospital HF

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Drammen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on various cancer types, including pancreatic ductal cancer, small-cell lung cancer, and advanced melanoma. Studies evaluate new combination therapies and treatment approaches.

  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Colon Cancer Treatment

Research emphasizes improving survival rates and treatment efficacy through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into cardiovascular diseases and preventive treatments. Trials explore new approaches for stroke prevention and management of heart conditions.

  • Atrial Fibrillation Management
  • Stroke Prevention
  • Atherosclerotic Disease

Focus on developing innovative antiplatelet therapies and investigating cardiovascular safety in various patient populations.

03 Chronic Disease Management

Studies addressing chronic conditions including Multiple Sclerosis, Crohn's Disease, and Rheumatoid Arthritis. Trials evaluate new therapeutic approaches and drug combinations.

  • COPD Treatment
  • Inflammatory Conditions
  • Metabolic Disorders

Research aims to improve disease control and patient outcomes through innovative treatment strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.